Concepts (211)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Renal Dialysis | 52 | 2026 | 952 | 12.480 |
Why?
|
| Kidney Failure, Chronic | 49 | 2026 | 941 | 11.680 |
Why?
|
| Peritoneal Dialysis | 9 | 2023 | 131 | 5.170 |
Why?
|
| Medicare | 18 | 2025 | 439 | 3.330 |
Why?
|
| Nephrologists | 4 | 2025 | 17 | 2.350 |
Why?
|
| Prospective Payment System | 5 | 2021 | 16 | 2.250 |
Why?
|
| United States | 45 | 2025 | 11815 | 1.920 |
Why?
|
| Ambulatory Care | 5 | 2021 | 407 | 1.820 |
Why?
|
| Hemodialysis, Home | 4 | 2022 | 13 | 1.820 |
Why?
|
| Economic Competition | 4 | 2023 | 14 | 1.640 |
Why?
|
| Ambulatory Care Facilities | 6 | 2021 | 236 | 1.450 |
Why?
|
| Health Facility Closure | 2 | 2021 | 8 | 1.350 |
Why?
|
| Delivery of Health Care | 5 | 2022 | 682 | 1.330 |
Why?
|
| Renal Insufficiency | 3 | 2023 | 252 | 1.320 |
Why?
|
| Health Care Sector | 3 | 2020 | 19 | 1.320 |
Why?
|
| Health Policy | 4 | 2020 | 227 | 1.290 |
Why?
|
| Nephrology | 4 | 2025 | 156 | 1.190 |
Why?
|
| Patient Readmission | 4 | 2017 | 423 | 1.160 |
Why?
|
| Reimbursement Mechanisms | 4 | 2023 | 36 | 1.130 |
Why?
|
| Hematinics | 2 | 2023 | 60 | 1.100 |
Why?
|
| Telemedicine | 2 | 2025 | 524 | 1.060 |
Why?
|
| Arteriovenous Shunt, Surgical | 3 | 2024 | 92 | 1.030 |
Why?
|
| Practice Patterns, Physicians' | 3 | 2021 | 775 | 1.010 |
Why?
|
| Fee-for-Service Plans | 2 | 2016 | 19 | 1.000 |
Why?
|
| Patient Satisfaction | 2 | 2021 | 460 | 0.990 |
Why?
|
| Medicaid | 6 | 2019 | 252 | 0.960 |
Why?
|
| Humans | 70 | 2026 | 131781 | 0.920 |
Why?
|
| Hemodiafiltration | 1 | 2025 | 17 | 0.900 |
Why?
|
| Financing, Government | 2 | 2023 | 33 | 0.890 |
Why?
|
| Health Expenditures | 4 | 2022 | 134 | 0.870 |
Why?
|
| Anemia | 2 | 2023 | 356 | 0.860 |
Why?
|
| Aged | 28 | 2025 | 21263 | 0.850 |
Why?
|
| Polycystic Kidney, Autosomal Dominant | 2 | 2014 | 13 | 0.820 |
Why?
|
| Benzazepines | 2 | 2014 | 44 | 0.810 |
Why?
|
| Hospitalization | 4 | 2021 | 1942 | 0.780 |
Why?
|
| Vitamin D | 2 | 2018 | 194 | 0.780 |
Why?
|
| National Health Programs | 1 | 2023 | 20 | 0.780 |
Why?
|
| Registries | 8 | 2022 | 1598 | 0.750 |
Why?
|
| Health Care Costs | 3 | 2020 | 400 | 0.670 |
Why?
|
| Accountable Care Organizations | 1 | 2020 | 7 | 0.670 |
Why?
|
| Middle Aged | 26 | 2025 | 28897 | 0.660 |
Why?
|
| Insurance, Health | 2 | 2018 | 140 | 0.640 |
Why?
|
| Hemodialysis Units, Hospital | 1 | 2020 | 9 | 0.640 |
Why?
|
| Health Facility Merger | 2 | 2019 | 8 | 0.640 |
Why?
|
| Renal Insufficiency, Chronic | 4 | 2020 | 848 | 0.630 |
Why?
|
| Attitude of Health Personnel | 1 | 2025 | 715 | 0.620 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 2 | 2019 | 743 | 0.610 |
Why?
|
| Male | 37 | 2025 | 65290 | 0.610 |
Why?
|
| Reimbursement, Incentive | 2 | 2023 | 48 | 0.600 |
Why?
|
| Specialization | 1 | 2019 | 75 | 0.590 |
Why?
|
| Models, Organizational | 1 | 2019 | 44 | 0.580 |
Why?
|
| Safety-net Providers | 1 | 2019 | 88 | 0.580 |
Why?
|
| Kidney Transplantation | 2 | 2021 | 572 | 0.580 |
Why?
|
| Female | 37 | 2025 | 71221 | 0.580 |
Why?
|
| Nurse Practitioners | 1 | 2019 | 50 | 0.570 |
Why?
|
| Physician Assistants | 1 | 2019 | 80 | 0.550 |
Why?
|
| Cost-Benefit Analysis | 5 | 2025 | 544 | 0.540 |
Why?
|
| Commerce | 1 | 2018 | 58 | 0.540 |
Why?
|
| Bariatric Surgery | 1 | 2019 | 155 | 0.520 |
Why?
|
| Delivery of Health Care, Integrated | 1 | 2019 | 144 | 0.520 |
Why?
|
| Physicians | 2 | 2023 | 634 | 0.510 |
Why?
|
| Insurance Coverage | 1 | 2017 | 117 | 0.500 |
Why?
|
| Quality Assurance, Health Care | 1 | 2018 | 210 | 0.500 |
Why?
|
| Cardiovascular Diseases | 3 | 2019 | 2082 | 0.500 |
Why?
|
| Hemoglobins | 2 | 2023 | 314 | 0.480 |
Why?
|
| Mobility Limitation | 1 | 2015 | 35 | 0.460 |
Why?
|
| Skilled Nursing Facilities | 1 | 2015 | 8 | 0.450 |
Why?
|
| Vascular Access Devices | 1 | 2014 | 35 | 0.430 |
Why?
|
| Office Visits | 1 | 2015 | 81 | 0.430 |
Why?
|
| Healthcare Disparities | 2 | 2024 | 502 | 0.420 |
Why?
|
| Health Resources | 1 | 2015 | 128 | 0.400 |
Why?
|
| Pravastatin | 1 | 2013 | 22 | 0.400 |
Why?
|
| Rhabdomyolysis | 1 | 2013 | 35 | 0.390 |
Why?
|
| Cohort Studies | 8 | 2019 | 5122 | 0.380 |
Why?
|
| Glomerular Filtration Rate | 2 | 2013 | 567 | 0.380 |
Why?
|
| Health Care Reform | 3 | 2020 | 52 | 0.380 |
Why?
|
| Employment | 2 | 2026 | 71 | 0.370 |
Why?
|
| Hyperparathyroidism | 1 | 2010 | 24 | 0.330 |
Why?
|
| Naphthalenes | 1 | 2010 | 38 | 0.330 |
Why?
|
| Adult | 14 | 2026 | 31710 | 0.330 |
Why?
|
| Substance-Related Disorders | 1 | 2015 | 491 | 0.330 |
Why?
|
| Residence Characteristics | 1 | 2013 | 293 | 0.320 |
Why?
|
| Multivariate Analysis | 4 | 2015 | 1406 | 0.320 |
Why?
|
| Ownership | 3 | 2019 | 36 | 0.320 |
Why?
|
| Retrospective Studies | 11 | 2025 | 17667 | 0.300 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 1 | 2015 | 650 | 0.280 |
Why?
|
| Atrial Fibrillation | 2 | 2025 | 734 | 0.270 |
Why?
|
| Quality-Adjusted Life Years | 3 | 2013 | 126 | 0.270 |
Why?
|
| Patient Reported Outcome Measures | 2 | 2021 | 221 | 0.270 |
Why?
|
| Cost Savings | 2 | 2020 | 78 | 0.270 |
Why?
|
| Time Factors | 7 | 2019 | 6279 | 0.260 |
Why?
|
| Diabetes Mellitus | 1 | 2015 | 891 | 0.260 |
Why?
|
| Qualitative Research | 3 | 2026 | 708 | 0.260 |
Why?
|
| Blood Vessel Prosthesis Implantation | 1 | 2015 | 743 | 0.260 |
Why?
|
| Stroke | 2 | 2025 | 1049 | 0.250 |
Why?
|
| Emergency Service, Hospital | 1 | 2015 | 1217 | 0.250 |
Why?
|
| Myocardial Infarction | 1 | 2013 | 999 | 0.230 |
Why?
|
| Factor Xa Inhibitors | 1 | 2025 | 59 | 0.220 |
Why?
|
| Parathyroid Hormone | 1 | 2025 | 77 | 0.220 |
Why?
|
| Forearm | 1 | 2024 | 38 | 0.220 |
Why?
|
| Pyridones | 1 | 2025 | 148 | 0.220 |
Why?
|
| Cross-Sectional Studies | 4 | 2024 | 3838 | 0.210 |
Why?
|
| Ferritins | 1 | 2023 | 109 | 0.200 |
Why?
|
| Markov Chains | 2 | 2013 | 100 | 0.190 |
Why?
|
| Pyrazoles | 1 | 2025 | 359 | 0.190 |
Why?
|
| Disease Progression | 3 | 2013 | 2221 | 0.190 |
Why?
|
| Patient Outcome Assessment | 1 | 2023 | 92 | 0.190 |
Why?
|
| Travel | 1 | 2023 | 129 | 0.190 |
Why?
|
| Treatment Outcome | 6 | 2025 | 12997 | 0.170 |
Why?
|
| Patient Care Bundles | 1 | 2021 | 24 | 0.170 |
Why?
|
| Iron | 1 | 2023 | 310 | 0.160 |
Why?
|
| China | 1 | 2021 | 287 | 0.160 |
Why?
|
| Neoplasms | 1 | 2015 | 2963 | 0.160 |
Why?
|
| Data Collection | 1 | 2022 | 372 | 0.160 |
Why?
|
| Propensity Score | 1 | 2021 | 265 | 0.160 |
Why?
|
| Health Facilities, Proprietary | 1 | 2019 | 3 | 0.160 |
Why?
|
| Logistic Models | 2 | 2016 | 1838 | 0.160 |
Why?
|
| Benzofurans | 1 | 2019 | 33 | 0.160 |
Why?
|
| Quinoxalines | 1 | 2019 | 39 | 0.150 |
Why?
|
| Medically Uninsured | 1 | 2019 | 77 | 0.150 |
Why?
|
| Patient Care | 1 | 2020 | 99 | 0.150 |
Why?
|
| Ezetimibe | 1 | 2019 | 94 | 0.150 |
Why?
|
| Decision Support Techniques | 2 | 2013 | 298 | 0.150 |
Why?
|
| Efficiency, Organizational | 1 | 2019 | 58 | 0.140 |
Why?
|
| Outpatients | 1 | 2020 | 266 | 0.140 |
Why?
|
| Imidazoles | 1 | 2019 | 222 | 0.140 |
Why?
|
| Policy Making | 1 | 2018 | 59 | 0.140 |
Why?
|
| Central Venous Catheters | 1 | 2018 | 51 | 0.140 |
Why?
|
| Risk Factors | 4 | 2018 | 10965 | 0.140 |
Why?
|
| Indians, North American | 1 | 2018 | 74 | 0.140 |
Why?
|
| Pandemics | 1 | 2025 | 1165 | 0.140 |
Why?
|
| Health Care Surveys | 1 | 2018 | 282 | 0.130 |
Why?
|
| Program Development | 1 | 2018 | 181 | 0.130 |
Why?
|
| Health Services Accessibility | 1 | 2023 | 698 | 0.130 |
Why?
|
| Physician's Role | 1 | 2019 | 165 | 0.130 |
Why?
|
| Primary Health Care | 1 | 2023 | 791 | 0.130 |
Why?
|
| Aged, 80 and over | 5 | 2025 | 6916 | 0.130 |
Why?
|
| Hemorrhage | 2 | 2025 | 498 | 0.130 |
Why?
|
| Hospitals | 1 | 2019 | 445 | 0.130 |
Why?
|
| Graft Survival | 1 | 2018 | 466 | 0.120 |
Why?
|
| Kidney | 4 | 2024 | 1309 | 0.120 |
Why?
|
| Cause of Death | 1 | 2018 | 510 | 0.120 |
Why?
|
| Program Evaluation | 1 | 2018 | 443 | 0.120 |
Why?
|
| Confidence Intervals | 1 | 2016 | 272 | 0.120 |
Why?
|
| Anticoagulants | 2 | 2025 | 595 | 0.120 |
Why?
|
| Heart Transplantation | 1 | 2022 | 833 | 0.120 |
Why?
|
| Hepatitis C, Chronic | 1 | 2019 | 367 | 0.110 |
Why?
|
| Chronic Disease | 1 | 2019 | 1235 | 0.110 |
Why?
|
| Patient Care Team | 1 | 2019 | 558 | 0.110 |
Why?
|
| Administration, Intravenous | 1 | 2015 | 170 | 0.110 |
Why?
|
| Antiviral Agents | 1 | 2019 | 813 | 0.100 |
Why?
|
| Risk | 2 | 2013 | 739 | 0.100 |
Why?
|
| Quality Improvement | 1 | 2020 | 707 | 0.100 |
Why?
|
| Public Health | 1 | 2016 | 277 | 0.100 |
Why?
|
| Heart-Assist Devices | 1 | 2022 | 991 | 0.100 |
Why?
|
| Life Expectancy | 1 | 2013 | 63 | 0.100 |
Why?
|
| Hypertension, Renal | 1 | 2012 | 30 | 0.100 |
Why?
|
| Drug Therapy, Combination | 2 | 2019 | 1171 | 0.100 |
Why?
|
| Drug Costs | 1 | 2013 | 62 | 0.100 |
Why?
|
| Heparin | 1 | 2014 | 206 | 0.090 |
Why?
|
| Young Adult | 4 | 2019 | 10102 | 0.090 |
Why?
|
| Prosthesis-Related Infections | 1 | 2015 | 194 | 0.090 |
Why?
|
| Proteinuria | 1 | 2012 | 106 | 0.090 |
Why?
|
| Age of Onset | 1 | 2013 | 631 | 0.090 |
Why?
|
| Morbidity | 1 | 2012 | 261 | 0.090 |
Why?
|
| Primary Prevention | 1 | 2013 | 175 | 0.090 |
Why?
|
| Kidney Diseases | 1 | 2016 | 482 | 0.090 |
Why?
|
| Proportional Hazards Models | 1 | 2015 | 1405 | 0.080 |
Why?
|
| Blood Vessel Prosthesis | 1 | 2015 | 472 | 0.080 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2014 | 1626 | 0.080 |
Why?
|
| Health Status | 1 | 2013 | 388 | 0.080 |
Why?
|
| Patient Discharge | 1 | 2014 | 507 | 0.080 |
Why?
|
| Biomedical Research | 1 | 2016 | 557 | 0.080 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2012 | 1078 | 0.080 |
Why?
|
| Odds Ratio | 1 | 2013 | 1235 | 0.080 |
Why?
|
| Heart Failure | 1 | 2022 | 2309 | 0.070 |
Why?
|
| Physician-Patient Relations | 1 | 2013 | 435 | 0.070 |
Why?
|
| Sex Factors | 1 | 2013 | 1347 | 0.070 |
Why?
|
| Thromboembolism | 1 | 2025 | 86 | 0.060 |
Why?
|
| Workplace | 1 | 2026 | 81 | 0.060 |
Why?
|
| Arm | 1 | 2024 | 74 | 0.050 |
Why?
|
| Hypertension | 1 | 2013 | 1360 | 0.050 |
Why?
|
| Follow-Up Studies | 1 | 2012 | 5297 | 0.050 |
Why?
|
| Anti-Bacterial Agents | 1 | 2015 | 2576 | 0.050 |
Why?
|
| Motivation | 1 | 2023 | 332 | 0.040 |
Why?
|
| Lactams, Macrocyclic | 1 | 2019 | 33 | 0.040 |
Why?
|
| Carbamates | 1 | 2019 | 66 | 0.040 |
Why?
|
| Cyclopropanes | 1 | 2019 | 75 | 0.040 |
Why?
|
| Amides | 1 | 2019 | 91 | 0.040 |
Why?
|
| Benchmarking | 1 | 2020 | 138 | 0.040 |
Why?
|
| Unemployment | 1 | 2018 | 23 | 0.030 |
Why?
|
| Hepacivirus | 1 | 2019 | 273 | 0.030 |
Why?
|
| Sulfonamides | 1 | 2019 | 296 | 0.030 |
Why?
|
| Incidence | 1 | 2025 | 3349 | 0.030 |
Why?
|
| Transplant Recipients | 1 | 2018 | 233 | 0.030 |
Why?
|
| Adolescent | 3 | 2019 | 20994 | 0.030 |
Why?
|
| National Institutes of Health (U.S.) | 1 | 2016 | 135 | 0.030 |
Why?
|
| Choice Behavior | 1 | 2016 | 132 | 0.030 |
Why?
|
| Patient Preference | 1 | 2016 | 146 | 0.030 |
Why?
|
| Genotype | 1 | 2019 | 2655 | 0.030 |
Why?
|
| Comorbidity | 1 | 2018 | 1600 | 0.020 |
Why?
|
| Electronic Health Records | 1 | 2019 | 810 | 0.020 |
Why?
|
| South Carolina | 1 | 2011 | 10 | 0.020 |
Why?
|
| North Carolina | 1 | 2011 | 65 | 0.020 |
Why?
|
| Severity of Illness Index | 1 | 2019 | 3094 | 0.020 |
Why?
|
| Georgia | 1 | 2011 | 46 | 0.020 |
Why?
|
| Age Factors | 1 | 2018 | 2872 | 0.020 |
Why?
|
| Serum Albumin | 1 | 2011 | 110 | 0.020 |
Why?
|
| Regression Analysis | 1 | 2011 | 773 | 0.020 |
Why?
|
| Veterans | 1 | 2019 | 1797 | 0.020 |
Why?
|
| Quality of Health Care | 1 | 2011 | 411 | 0.020 |
Why?
|